Imcheck Therapeutics
imchecktherapeutics.com
Immunology & Inflammation Therapeutics
Health Care
Oncology Therapeutics
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Kurma Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Lever Bio aims to translate groundbreaking discoveries in immuno-oncology into next-generation cancer immunotherapies.
Company Management Team Board of Directors Scientific Advisory Board Clinical Advisory Board Company History Investors Science Biology…
We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
At Oxford BioTherapeutics, we are dedicated to pioneering the next generation of oncology treatments through targeted therapies, including…
Our Tumor Activated Permeability (TAP) Platform produces weakly-acidic derivatives of known oncology drugs that already work. It preserves…
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Kurma PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Ipsen To Buy ImCheck Therapeutics From EQT In A Deal Valued Up To €1 Billion
EQT Life Sciences announced that global biopharmaceutical company Ipsen has entered into a definitive agreement to acquire its portfolio company, ImCheck Therapeutics, for an upfront payment of €350 million and additional downstream payments, bringing the
Read more
Report
Report
EQT Life Sciences
EQT Life Sciences is pleased to announce that Ipsen (Euronext: IPN; ADR: IPSEY) has entered into a definitive agreement to acquire its portfolio company ImCheck Therapeutics for EUR 350 million at closing, with a total transaction value of up to USD 1 bil
Read more
Report
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfi
Read more
Report
Report
Imcheck Therapeutics SAS Institution outputs
The Nature Index tracks the affiliations of high-quality scientific articles. Updated monthly, the Nature Index presents research outputs by institution and country. Use the Nature Index to interrogate publication patterns and to benchmark research perfor
Read more
Report